Raltegravir News and Research

RSS
Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Are COVID-19 medications safe in pregnancy?

Are COVID-19 medications safe in pregnancy?

Novel natural compounds may help treat COVID-19, study suggests

Novel natural compounds may help treat COVID-19, study suggests

Research uncovers how HIV develops resistance to key drugs

Research uncovers how HIV develops resistance to key drugs

Most preferred drug for HIV may not be as safe as suggested

Most preferred drug for HIV may not be as safe as suggested

Researchers report first randomized trial results of 'kick and kill' approach to treat HIV

Researchers report first randomized trial results of 'kick and kill' approach to treat HIV

New HIV prevention guidelines from Canada released

New HIV prevention guidelines from Canada released

Nearly half of newly-infected HIV patients experience neurologic issues

Nearly half of newly-infected HIV patients experience neurologic issues

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Merck announces FDA approval of ISENTRESS for oral suspension

Merck announces FDA approval of ISENTRESS for oral suspension

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.